Lupin Q1 FY27: A record quarter, plus a cautious FY27 script

Lupin opened FY27 with a record quarter. Net sales for Q1 FY27 rose 33.3% year on year to INR 8,217 crore. EBITDA, excluding forex and other income, increased 50.1% to INR 2,464 crore, translating into a 30.0% margin. Net income after adjusting for non-controlling interest came in at INR 1,415 crore.

Management also set the tone for the rest of the year. Despite the exceptional start, the company reiterated its earlier FY27 guidance of high single-digit revenue growth and EBITDA margins around 25%, reflecting expected moderation in the US due to higher competitive intensity in key products.

A geographically diversified quarter, led by the US

The quarter’s growth was not restricted to one geography. Lupin highlighted strong year-on-year growth across key markets, with management stating that organic revenue growth excluding the US was 20% plus, supported by double-digit performance in India, Other Developed Markets and Emerging Markets.

In the investor presentation’s revenue mix, the United States accounted for 42% of Q1 FY27 sales, followed by India at 29%. Other Developed Markets contributed 14%, Emerging Markets 12%, and API 3%.

The US business delivered USD 366 million in Q1 FY27, up 30% year on year in constant currency terms. Management attributed growth to higher volumes in the base portfolio and benefits from products such as Tolvaptan, partially offset by increased competition in Mirabegron.

But the company was careful to reset expectations for the next few quarters. Lupin guided FY27 US sales in the range of USD 1.1 billion to USD 1.2 billion. On the call, management explained that Q1 did not see additional competition in Tolvaptan, while from Q2 onwards the company expects new entrants and pricing pressure. Management also indicated that Mirabegron pressure, already visible in Q1, would be a full-quarter impact from Q2.

India remains a steady engine with chronic focus

India sales grew 13.9% year on year to INR 2,380 crore in Q1 FY27. The core prescription business grew 15.1% versus the India Pharma Market growth of around 13.5%, translating into about 1.1 times market growth.

The company continues to lean into chronic therapies. Chronic contributed about 67% of the India portfolio in Q1 FY27, up from about 65% in FY26, and management has set a target to increase the share to about 70% over the next five years.

Within therapy performance, management highlighted outperformance in Anti-Diabetes and Cardiology, with growth at 1.8 times and 1.2 times category growth, respectively. The diabetes segment grew 31.8% year on year, supported by leadership in Huminsulin and the launch of Semaglutide injection. Management also mentioned that vial and oral dosage forms of Semaglutide are expected to be launched in the second half of FY27.

Lupin launched seven products in Q1 FY27 and plans to launch 20 plus products in FY27.

Profitability, guidance, and what may normalise

Gross profit excluding other operating income improved to 74.6% of sales from 71.3% a year ago. The CFO attributed the improvement to better product mix, higher profitability in India, increased volumes, and cost improvements and efficiencies.

Other operating income declined year on year, which management linked primarily to lower export benefits from PLI schemes.

Even with the strong Q1 margin performance, management reiterated full-year EBITDA margin guidance around 25%. On the call, the CFO linked this caution to the expected impact of US competition on key products, and also to cost pressures influenced by geopolitical conditions.

R&D spend was INR 608 crore in Q1 FY27, or 7.4% of sales. For the full year, management expects R&D to be around 8% of sales.

Pipeline focus: complex generics, biosimilars, and selective specialty bets

Lupin continues to position its future US growth around complex platforms and higher barriers to entry. The company highlighted its inhalation capabilities across MDIs, DPIs, soft-mist inhalers, nasal sprays and nebulizers, along with injectables spanning peptides, iron colloids, depot and liposomal products, and 505(b)(2) injectables.

On the call, management discussed a set of potential launches and filings across FY27 to FY29, including a planned Pegfilgrastim contribution in the second half of FY27 and multiple respiratory, injectable and nasal spray opportunities.

Biosimilars were positioned as a material multi-year opportunity, with management indicating that across the US and Europe, the next three years could represent a couple of hundred million dollars of biosimilar opportunity across a few products.

In Europe, the company is now consolidating VISUfarma from this quarter. Management indicated that Other Developed Markets growth could be in the range of 10% to 20% over the next couple of years, with margins expected to expand as scale improves.

Balance sheet and capital allocation signals

Working capital increased to 90 days as of June 30, 2026 from 87 days as of March 31, 2026. Net cash declined to INR 2,831 crore from INR 4,636 crore, largely due to the closure of the VISUfarma acquisition.

Management stated it continues to explore strategic allocation of capital aligned with the company’s long-term mission, including on the specialty front.

Takeaways

Lupin’s Q1 FY27 numbers reflect strong execution and a favourable mix, especially in the US and continued momentum in India and other markets. At the same time, the management commentary makes it clear that FY27 is expected to be a year of transition in the US as competitive intensity increases in key products.

The company’s ability to deliver on its complex generics, biosimilars and 505(b)(2) pipeline, alongside steady India growth and Europe scale-up with VISUfarma, will likely determine how quickly Lupin can move back to a stronger growth trajectory from FY28 as management expects.